We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Below we will list the departments and units that form part of Vall d’Hebron Hospital and the main diseases that we treat. We will also make recommendations based on advice backed up by scientific evidence that has been shown to be effective in guaranteeing well-being and quality of life.
Vols saber com serà la teva estada a l’Hospital Universitari Vall d’Hebron? Aquí trobaràs tota la informació.
El Dr. Mendoza recollint el premi Investigador Emergent 2023
Research led by the doctor has stopped unnecessary medicalisation with aspirin during pregnancy.
Dr. Manel Mendoza, head of the Placental Insufficiency Unit within the Specialised Obstetrics Unit at Vall d'Hebron University Hospital, and researcher of the Maternal and Fetal Medicine research group at Vall d'Hebron Research Institute (VHIR), has received the Emerging Researcher Award given annually by the International Aspirin Foundation.
The Foundation highlighted Dr Mendoza's participation as principal investigator in the clinical trial that demonstrated the efficacy of the sFIt-1/PIGF indicator in detecting the false positives in the preeclampsia screening and, therefore, stopping their treatment.
Preeclampsia is a serious multisystem disorder that affects between 2% and 4% of pregnancies. For years, a first trimester screening has been carried out in Catalonia, where 10-15% of all pregnant women are considered to be at high risk of preeclampsia and are recommended to take aspirin every day until the end of pregnancy. Due to the severity of the condition, the relative safety of aspirin and the need to start prevention before 16 weeks, despite the large number of false positives, it is considered better to offer treatment to all high-risk patients rather than risk not medicating pregnancies that could develop the condition.
Thanks to Dr Mendoza's research, with a simple blood test between 24 and 28 weeks, false-positive screening can be identified, about 90% of patients on preventive treatment, and these pregnant women can stop taking daily aspirin. This test does not give reliable results until the second trimester, and between tests, pregnant women are advised to undergo treatment, as the benefits outweigh the risks.
Dr Andrew Chan, head of the Foundation's scientific advisory board, highlighted the importance of research that "prevents preeclampsia and reduces the risk of haemorrhage". He added that the use of aspirin in these cases is a perfect example "of a low-cost intervention that has a huge positive impact on public health".
Dr Mendoza expressed his gratitude for the award and hoped it is the first step towards "a more physiological and less medicalised approach to pregnancy".
Dr Mendoza hopes it is the first step towards "a more physiological and less medicalised approach to pregnancy".
Obstetrics and Reproductive Medicine, Children's Hospital and Woman's Hospital
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.